In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.

Liu Q, Zhang H, Zhou G, Xie S, Zou H, Yu Y, Li G, Sun D, Zhang G, Lu Y, Zhong Y

International journal of pharmaceutics25 Jul 2010Cited by 45 (Europe PMC)

PMID20650309DOI10.1016/j.ijpharm.2010.07.015PepBankPUB-20650309

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In rats, the optimal Talpha1 implant showed a low initial release of 29.3% at 24 h, then slow continuous release up to 28 days.
In plain wordsIn rats, the best implant released 29.3% of thymosin alpha‑1 on the first day, then released it slowly for up to 28 days.
Peptide
Thymosin alpha-1
Outcome
Not applicableIn vivo release of Talpha1 from optimal ISFI
Study
ratn: not reported in source
Sprague-Dawley rats, subcutaneous injection of Talpha1-loaded ISFI
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · subcutaneousAs given in this study (rat).
Measurements
Initial release
29.3%
24 h, optimal ISFI
Source sentences
Summary
The optimal prescription of our study showed a low initial release of 29.3% (24 h), followed by a slow and continuous drug release up to 28 d in vivo.
2 context sentences(design, population, supporting numbers)
Summary · context
The effects of Talpha1 pre-encapsulation, PLGA molecular weight, PLGA concentration and organic solvents composition on the in vivo Talpha1 release were evaluated by subcutaneously injecting Talpha1-loaded ISFI into Sprague-Dawley Rats.
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
Report a problemFND-2065030902
02AnimalAnimal study (in vivo)Efficacy outcome
In cyclophosphamide-induced immunosuppressed BALB/c mice, Talpha1-loaded ISFI significantly increased the thymic index.
In plain wordsIn immunosuppressed mice, the thymosin alpha‑1 implant raised the thymus index.
Peptide
Thymosin alpha-1
Outcome
IncreaseThymic index in cyclophosphamide-induced immunosuppressed mice
Study
mousen: not reported in source
Immunosuppressive BALB/c mice induced by cyclophosphamide
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Talpha1-loaded ISFI significantly increased the thymic index and spleen index of immunosuppressive mice.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacological efficacy of Talpha1-loaded ISFI was examined using immunosuppressive BALB/c mice induced by cyclophosphamide.
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
Report a problemFND-2065030905
03AnimalAnimal study (in vivo)Efficacy outcome
In cyclophosphamide-induced immunosuppressed BALB/c mice, Talpha1-loaded ISFI significantly increased the spleen index.
In plain wordsIn immunosuppressed mice, the thymosin alpha‑1 implant raised the spleen index.
Peptide
Thymosin alpha-1
Outcome
IncreaseSpleen index in cyclophosphamide-induced immunosuppressed mice
Study
mousen: not reported in source
Immunosuppressive BALB/c mice induced by cyclophosphamide
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Talpha1-loaded ISFI significantly increased the thymic index and spleen index of immunosuppressive mice.
2 context sentences(design, population, supporting numbers)
Summary · context
The pharmacological efficacy of Talpha1-loaded ISFI was examined using immunosuppressive BALB/c mice induced by cyclophosphamide.
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
Report a problemFND-2065030906
04LabIn vitro (cells)Safety outcome
Talpha1-loaded ISFI showed low cytotoxicity in a CCK-8 assay.
In plain wordsIn lab tests on cells, the thymosin alpha‑1 implant showed low toxicity.
Peptide
Thymosin alpha-1
Outcome
Not applicableCytotoxicity of Talpha1-loaded ISFI (CCK-8 assay)
Study
n: not reported in source
CCK-8 cytotoxicity assay
Outcome group
Adverse events · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Talpha1-loaded ISFI showed low cytotoxicity as tested by CCK-8 assay.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
Report a problemFND-2065030904

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

05LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other
Implants with chitosan pre-encapsulated Talpha1, higher-molecular-weight PLGA at higher concentration and more triacetin showed a lower initial release and a longer sustained release.
In plain wordsIn lab and animal formulation tests, certain implant designs released thymosin alpha‑1 more slowly and for longer.
Peptide
Thymosin alpha-1
Outcome
Not applicableEffect of formulation parameters on initial and sustained release
Study
n: not reported in source
PLGA in situ forming implants
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The ISFI composed of Talpha1 pre-encapsulated with chitosan, higher molecule-weight PLGA at higher concentration and more triacetin showed a lower initial release and a longer sustained release period.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2065030901
06LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other
An in vitro release device showed good correlation with in vivo Talpha1 release (linear correlation coefficient 0.9899).
In plain wordsIn lab tests, a release device matched the release seen in rats closely.
Peptide
Thymosin alpha-1
Outcome
Not applicableIn vitro to in vivo release correlation
Study
n: not reported in source
In vitro release device
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Linear correlation coefficient
0.9899
in vitro vs in vivo release
Source sentences
Summary
An in vitro release device was designed to mimic the in vivo release of Talpha1, and good correlation was observed between the in vitro and in vivo releases, with the linear correlation coefficient of 0.9899.
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of this study was to develop poly(lactide-co-glycolide) (PLGA) based in situ forming implants (ISFI) for controlled release of thymosin alpha 1 (Talpha1).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2065030903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.